Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.
Why Pfizer acquired Amplyx Pharmaceuticals?
Amplyx’s most advanced treatment is an antifungal called fosmanogepix, which the companies claim offers a new way to treat potentially life-threatening invasive infections caused by molds and yeasts.
Fosmanogepix is currently in Phase 2 clinical trials evaluating the safety and efficacy of both intravenous (IV) and oral formulations for the treatment of patients with life-threatening invasive fungal infections caused by molds, yeasts and rare molds (e.g., Aspergillus spp, Candida spp including Candida auris, Fusarium spp. and Scedosporium spp). Fosmanogepix has demonstrated broad-spectrum activity in-vitro and has shown wide distribution to various tissues including the brain, lung, kidney and eye. With both IV and oral formulations in development, Fosmanogepix may allow for the transition from IV to oral, thus potentially enabling, for the benefit of patients, the continuation of treatment outside the hospital.
In addition to Fosmanogepix, with this acquisition, Pfizer has secured ownership of Amplyx’s early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies.
The purchase, terms of which weren’t disclosed, follows an equity investment Pfizer made in Amplyx’s Series C financing in December 2019. Other investors in that round included Adage Capital Management, BioMed Ventures and Sofinnova Investments.